Capecitabine and pyrrolitinib have some anti-cancer effects, but the specific efficacy is more related to the stage of the disease. The drugs should be applied under the guidance of doctors. Capecitabine and pyrrolitinib are commonly used in the treatment of breast cancer, of which capecitabine belongs to chemotherapy drugs; pyrrolitinib is a targeted drug against HER2 (Human Epidermal Growth Factor Receptor-2) target. In clinical practice, they can be used as adjuvant treatment for breast cancer after surgery, for advanced patients with no chance of surgery, and for patients with recurrence. The specific efficacy depends on the patient’s stage. For example, the five-year survival of stage I patients is 90%~95%; while stage IV is about 20%. Capecitabine common adverse reactions are diarrhea, cardiotoxicity, hyperbilirubinemia, etc. Note that patients with severe hepatic and renal impairment avoid use; pyrrolitinib has diarrhea, nausea, vomiting, etc.. Therefore, during the application of the drug, pay attention to test the electrocardiogram, liver and kidney function, and so on.